Precision targeted therapy for EGFR mutation‐positive NSCLC: Dilemmas and coping strategies

The most common driver gene mutation in patients with non‐small‐cell lung cancer (NSCLC) is an epidermal growth factor receptor (EGFR) mutation. With the introduction of EGFR‐tyrosine kinase inhibitors, the treatment prospects and prognosis of NSCLC patients with EGFR‐sensitive mutations have signif...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Ying, Bai, Rilan, Cui, Jiuwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151140/
https://www.ncbi.nlm.nih.gov/pubmed/37005552
http://dx.doi.org/10.1111/1759-7714.14858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151140/
https://www.ncbi.nlm.nih.gov/pubmed/37005552
http://dx.doi.org/10.1111/1759-7714.14858

Ejemplares similares